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increased thoracic aortic size. Our observations had a main
limitation: because the present study was based on cross-sectional
data, it is difficult to prove that OSA accelerates aortic expansion.
The present study indicates that OSA could contribute to
greater thoracic aortic size.
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Letters to the Editor
Limitations of Angiographic
Predictors of Bypass Graft Patency
I compliment the work of Glineur et al. (1) on advancing our
appreciation of the physiologic predictors of 6-month patency rates
of bypass grafts to the right coronary artery. The patency of the
gastroepiploic artery (GEA) had a significant association with
minimal luminal diameter (MLD) and percent diameter stenosis,
angiographic features that did not affect saphenous vein graft
patency rates as much. A larger MLD (1.4 mm) and the percent
diameter stenosis (55% narrowing) predicted GEA graft closure.
The accompanying editorial by Sabik and Blackstone (2) expertly
reviewed the evidence for competitive flow and coronary artery
bypass graft patency, explaining some of the factors in play for the
outcomes reported by Glineur et al. (1).
Although competitive flow between native and grafted coronary
vessels has been known to surgeons for many years as a cause of
graft failure (3–5), the prediction of graft patency on the basis of
the physiology of competitive flow should not be judged by
angiography alone. The numerous studies on intracoronary pres-
sure and intravascular ultrasound imaging reinforce the failure of
the angiogram to provide important physiologic and true anatomic
information, especially for intermediately severe stenoses (6,7).
Using angiography as a surrogate for physiologic activity is often
erroneous and, at this time, is an imprecise technique when
addressing physiologic mechanisms as described by Sabik et al. (5)
and others (3,4). The competing flow potential of the native artery
with vein graft flow can be directly measured by coronary pressure
or Doppler flow in patients in the cardiac catheterization labora-
tory (6,8).
The measurement of hyperemic translesional pressure ratio,
called fractional flow reserve (FFR) (8,9), has been applied to study
the fate of coronary bypass grafts with striking results. Confirming
the relevance of the physiologic stenosis severity and graft patency,
Botman et al. (10) report the 1-year follow-up of 164 patients
undergoing coronary bypass grafts. All vessels grafted had FFR
measured beforehand with the pressure sensor angioplasty guide-
wire in the catheterization laboratory. At 1 year, 9% of grafts on
functionally significant lesions were occluded, whereas 21% of
grafts on functionally nonsignificant lesions were occluded. A
significant graft occlusion rate was observed for grafted vessels with
near normal physiology (FFR 0.80, normal  1.0). The angio-
graphic percent diameter narrowings displayed a similar but less
precise correlation with graft failure. The findings from Botman et
al. (10) again emphasize what is generally appreciated but unmea-
sured: that is, the physiologic impact of intermediately severe
stenosis remains unknown by angiography.
Whereas the angiographic descriptor of MLD provided by
Glineur et al. (1) is an advance over measurements of stenosis
diameter (even if using a quantitative angiographic imaging sys-
tem), the precise pressure across stenosis can be obtained often
without difficulty by most interventional cardiologists. Certainly,
severe narrowings and total occlusions do not need such direct
measurements, but the physiologic assessment of intermediate
lesions can assist selection of the appropriate bypass graft should
the surgeon have an interest in this approach (11).
Sabik and Blackstone (2) note that using only maximal coronary
artery stenosis would not adjust for coronary artery size, whereas
MLD does this to a larger extent. However, neither MLD of the
reference lumen diameter nor percent lumen diameter narrowing
truly reflects competitive flow physiology. Although I recognize
this might not be possible in many clinical settings, I believe
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angiographic parameters cannot and should not be used as a
surrogate for coronary flow.
Finally, recent data by Sant’Anna et al. (12) challenge our
assumptions regarding whether angiographic 3-vessel disease is
truly physiological 3-vessel disease. Of the 250 patients undergo-
ing angiography, when the 27% of patients with angiographic
3-vessel disease had FFR measured in all 3 of these vessels, only
9% were found to have physiologically significant 3-vessel coronary
disease. Had bypass grafting been performed, a considerable
incidence of graft failure would be expected at follow-up. Fortu-
nately, in this setting graft failure is often clinically silent with the
consequences of graft closure across nonsignificant lesions revert-
ing to the native vessel, which remains patent and functional
(unless the lesion progresses).
Whereas the debate about the use of the GEA graft continues,
a critical question before the surgery for those vessels with
intermediately severe stenoses should be answered by direct phys-
iologic measurements: is a graft on this particular vessel going to be
of any use if the physiology is nearly normal (13)?
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Reply
Dr. Kern wisely raised several points that were not discussed in our
article (1). We are convinced of the interest of fractional flow
reserve (FFR) as a tool to asses the physiological relevance of
coronary stenoses, and we recently used this tool to compare the
resistance to blood flow of several coronary graft configurations
(2,3). Unfortunately, if all patients referred to bypass surgery
underwent a pre-operative angiographic evaluation and if most of
those angiographic documents could be analyzed quantitatively,
very few patients would be referred to surgery with a full mapping
of FFR on the different coronary segments.
In daily clinical practice, the use of FFR remains generally
restricted to the evaluation of stenoses of intermediate severity and
mainly in patients with 3-vessel disease who are planned to be
treated by interventional cardiology. For patients referred to
surgery with a 2- or 3-vessel disease, the decision to measure FFR
for an intermediate stenosis associated with angiographically severe
narrowing on other coronary segments is much less frequent,
because the surgical indication is already present, on the basis of
the critical lesions. In these cases, most cardiac surgeons choose to
graft the intermediate lesion as well, even if this bypass is at risk of
competitive flow. This attitude, although somewhat empirical, is
based on the low risk expected from the possible occlusion of such
nonfunctional grafts, on the hope that these grafts will remain
patent long enough to provide some help in the case of progression
of the intermediate lesion, and on the fear of a redo intervention,
if lesion severity is underestimated. It still remains uncertain
whether this is preferable to a more conservative attitude consisting
of graft implantation only on severely narrowed coronary segments.
Several observations have illustrated the capacity of the internal
thoracic artery (4) or right gastroepiploic artery (RGEA) (5) to
recover function in the long term after having been found not
functional (string sign) at early follow-up. This capacity seems
related to endothelial protection mechanisms that are probably less
prominent or totally absent in saphenous vein graft. Considering
the natural progression of the disease on native vessels, this
property could act in favor of RGEA in the longer term. The
ongoing angiographic re-evaluation of the grafts at 3 years post-
operatively could thus provide information susceptible to clarifying
the meaning of these early findings, particularly in RGEA grafts
with a balanced flow.
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